Affordable Access

deepdyve-link
Publisher Website

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Authors
  • Leder, Benjamin Z
  • O'Dea, Louis St L
  • Zanchetta, José R
  • Kumar, Prasana
  • Banks, Kathleen
  • McKay, Kathleen
  • Lyttle, C Richard
  • Hattersley, Gary
Type
Published Article
Journal
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Publication Date
February 2015
Volume
100
Issue
2
Pages
697–706
Identifiers
DOI: 10.1210/jc.2014-3718
PMID: 25393645
Source
Medline
License
Unknown

Abstract

Compared with placebo, 24 weeks of daily sc abaloparatide increases BMD of the lumbar spine, femoral neck, and total hip in a dose-dependent fashion. Moreover, the abaloparatide-induced BMD increases at the total hip are greater than with the marketed dose of teriparatide. These results support the further investigation of abaloparatide as an anabolic therapy in postmenopausal osteoporosis.

Report this publication

Statistics

Seen <100 times